Literature DB >> 8805680

Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride.

V Witko-Sarsat1, R C Allen, M Paulais, A T Nguyen, G Bessou, G Lenoir, B Descamps-Latscha.   

Abstract

The present study addresses the question of a possible linkage between the cystic fibrosis (CF) genetic autosomal recessive disorder and disturbance in neutrophil function. Neutrophil-dominated chronic airway inflammation is present at an early age in children with CF, even in the absence of detectable infection. As evidenced by extracellular superoxide anion release (measured by lucigenin luminescence) or intracellular hydrogen peroxide production (measured by 2',7'-dichlorofluorescein (DCF) fluorescence), no significant difference in the nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity of isolated neutrophils was observed in noninfected CF children (homozygotes), their mothers or fathers (CF heterozygotes), and controls. In contrast, both myeloperoxidase (MPO)-dependent oxygenation activity (measured by luminol luminescence) and chloramine release were increased significantly in both CF homozygotes and heterozygotes as compared with controls. In the presence of either amiloride (a sodium channel inhibitor and sodium/proton antiport blocker) or EIPA (5-ethyl-N-isopropyl-amiloride, a specific inhibitor of the antiport), or choline buffer, intracellular MPO activity was decreased significantly in controls and in the CF homozygotes and heterozygotes, thus bringing intracellular MPO-dependent activity in CF subjects back to the level of controls. Extracellular release of MPO, measured by an ELISA to provide an activity-independent assessment of the enzyme, was increased only in CF homozygotes, and was decreased by amiloride and choline buffer, but not by EIPA. We conclude that a modification of intracellular pH and/or ionic concentrations may be related to the altered MPO enzymatic activity observed in CF neutrophils.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805680

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.

Authors:  Jonas C Schupp; Sara Khanal; Jose L Gomez; Maor Sauler; Taylor S Adams; Geoffrey L Chupp; Xiting Yan; Sergio Poli; Yujiao Zhao; Ruth R Montgomery; Ivan O Rosas; Charles S Dela Cruz; Emanuela M Bruscia; Marie E Egan; Naftali Kaminski; Clemente J Britto
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

2.  Abnormalities in the pulmonary innate immune system in cystic fibrosis.

Authors:  Theo J Moraes; Jonathan Plumb; Raiza Martin; Eric Vachon; Vera Cherepanov; Adeline Koh; Carola Loeve; Jenny Jongstra-Bilen; Joanna H Zurawska; Julianne V Kus; Lori L Burrows; Sergio Grinstein; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11-17       Impact factor: 6.914

Review 3.  Update in Cystic Fibrosis 2018.

Authors:  Bonnie W Ramsey; Gregory P Downey; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

4.  CFTR inhibition provokes an inflammatory response associated with an imbalance of the annexin A1 pathway.

Authors:  Jesmond Dalli; Guglielmo Rosignoli; Richard P G Hayhoe; Aleksander Edelman; Mauro Perretti
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

5.  Reduced iC3b-mediated phagocytotic capacity of pulmonary neutrophils in cystic fibrosis.

Authors:  M R Morris; I J M Doull; S Dewitt; M B Hallett
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  Exposure of Pseudomonas aeruginosa to bactericidal hypochlorous acid during neutrophil phagocytosis is compromised in cystic fibrosis.

Authors:  Nina Dickerhof; Vivienne Isles; Philip Pattemore; Mark B Hampton; Anthony J Kettle
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

7.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

8.  Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils.

Authors:  Yun Zhou; Kejing Song; Richard G Painter; Martha Aiken; Jakob Reiser; Bruce A Stanton; William M Nauseef; Guoshun Wang
Journal:  J Innate Immun       Date:  2013-03-06       Impact factor: 7.349

9.  Neutrophils in cystic fibrosis display a distinct gene expression pattern.

Authors:  Minou Adib-Conquy; Thierry Pedron; Anne-France Petit-Bertron; Olivier Tabary; Harriet Corvol; Jacky Jacquot; Annick Clément; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

Review 10.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.